Eosinophil differentiating activity in sera of patients with AIDS under recombinant IL-2 substitution.
An increase in circulating eosinophils was observed in patients with AIDS or ARC who were substituted for a period of 14 days with exogenous recombinant IL-2 in the context of a Phase I/II study. IL-2 exerts a broad range of biological properties and enhances the production of a variety of other cytokines, i.e., factors for haemopoietic cell growth and differentiation. After having excluded a direct effect of r IL-2 on haemopoietic precursor cells in semi-solid agar cultures, we developed a liquid culture system and studied the effect of patients' sera collected at different time intervals before, during and after r IL-2 substitution on cell differentiation of normal human bone-marrow cells in vitro. Patients' eosinophilia was preceded by a detectable activity in the sera which induced light-density, non-adherent bone-marrow cells to differentiate into the eosinophil lineage and was assessed by the presence of eosinophil primary granules or Luxol-fast blue positive granules. Thus, these in vitro data suggest the presence of circulating mediator(s) enhancing eosinophil production and differentiation in response to in vivo substitution of r IL-2.
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000150:complications / Q000473:pathology* / Q000628:therapy; D001853:Bone Marrow / Q000502:physiology; D002454:Cell Differentiation; D004802:Eosinophilia / Q000209:etiology; D004804:Eosinophils / Q000473:pathology*; D006410:Hematopoiesis; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D008206:Lymphatic Diseases / Q000097:blood / Q000150:complications / Q000473:pathology / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use*
D007376:Interleukin-2; D011994:Recombinant Proteins